Pharmaceutical Industry Analysis

In this chapter a basic comprehension of how the pharmaceutical industry will be identified and which models will be used to analyse it will be directed at the audience.

1. 1 Explanation of Industry

The most significant definition of industry was given by Michael Porter in 1979: a "band of competition producing substitutes that are close enough that the behaviour of any organization affects each one of the others either directly or indirectly. "

Later, Porter identified the word more exactly as "several companies offering products or services that are close substitutes for each and every other, that is, products or services that gratify the same basic customers' needs. " This new meaning emphasizes the importance of industry edges and industry's role as a market supplier or producer of goods and services, as distinguished from a market, thought as a consumer of goods and services.

Furthermore, inside every industry there are groups of companies that follow similar strategies, defined by Michael S. Hunt in his unpublished 1972 Ph. D. dissertation as tactical communities. Between these groupings there are differences in entry obstacles, bargaining electricity with potential buyers and suppliers and skills and resources. Proper groups compete keenly against one another within the industry because of this of these dissimilarities.

1. 2 Models to Analyse the Industry and its own Environment

The literature agrees that understanding of the industry structure is vital to creating a firm's strategy and has a greater influence on the firm's performance than whether it is business-specific or corporate-parent. The comprehension of the framework requires analyses of the industry's life routine. It also requires step-by-step political, legal, technological, communal and financial analyses as well as the five travelling pushes of business, provided by Michael Porter. By utilizing these analysis techniques, additionally it is possible to foresee changes in industry competition and success as time passes.

1. 2. 1 Industry Life Routine Analysis

There will vary phases during the development of a business. Every phases is seen as a a different conditions which make competition assumes different the proper execution. Through studying the life cycle, the industry realizes its stake in the market and its affect on consumers. The industry life pattern model includes four different stages: introduction, growth, maturity and decline.

The first phase, called benefits, is seen as a a low demand, whereas prices are high because of firm's inability to realize economies of size. For this reason earnings are low and deficits are possible credited to high amount of purchases in new categories. Barriers to accessibility are primary based on technology and competencies. Strategy is focused mainly on R&D and development, with the goal of improving novelty and quality. Competition, seduced by the increasing demand, try to replicate the new product.

In the second phase, growth, the utilization of the product is lengthened, demand expands, prices decline scheduled to economies of level, barriers to access are lower and the risk of new admittance is high. At this period the technology is usually not exclusive property of one or more companies, and the principal a reaction to competition is marketing expenses and initiatives; profits are not high because prices decrease as competitors enter into the market.

There is a transition period, or shake-out, between your second and the third phases. The shake-out requires finding and using all investment opportunities, because the market is near saturation and demand grows up more slowly.

In the 3rd period, maturity, market expansion is low or non-existent, and the concentration shifts to attaining market talk about; demand is represented only by the substitution of products, investment in R&D lowers and there is little development.

In this phase organizations seek cost reductions, and competition is situated mostly on advertising and quality as a result of low differentiation between products. Big companies acquire smaller players, while others are required to exit. As a consequence of high hurdle to entry, the risk of new entrants are low.

The last phase is drop, so called due to continued decline popular. Industries arrive at this stage for a variety of reasons. Included in these are an alteration in communal behaviours, demographic changes, international competition, technologies and increased customer knowledge. The buying process is based generally on price somewhat than innovation. Because of this, profit and income decline, and the industry all together may be supplanted.

1. 2. 2 Infestations Analysis

The term "PEST" is an acronym of several aspects that impact business activities at any given point in time. An industry runs under Politics, Economic, Friendly and Technological conditions. These conditions are identify and analyzed using the Infestations Analysis technique. Because of the independent impact on any industry, it is essential that each be considered individually.

The political aspect of analysis encompasses various factors that impact business activities in confirmed country at several levels: nationwide, sub-national and supranational levels. Included in these are trade insurance policies control imports, exports and international business lovers, government possession of industry, frame of mind toward monopolies and competition and trade guidelines.

Hence, inability to consider these policies may cause loss of income due to taxes or penalty fees. Government steadiness is also very important, because it eradicates the potential risks associated with wars and conflicts. For a business to thrive, politics steadiness must be uncompromising; often, sales and business activities will be uncertain, and buyers will eventually lose interest. The inner political issues in any country effect the operating of business.

Politics predicated on race or religious beliefs may define the course for certain industries, particularly if an industry comes short of political goals. Elections and changes in command also affect an industry's strengths and opportunities and thus should be considered during the research. Furthermore to interior issues, international stresses and influences may affect some market sectors, such as environmental degradation or product safety.

Another factor is terrorism. Though unusual in many countries, poor or unstable governance may appeal to terrorist activities, vengeful or elsewhere, which can have undesireable effects on the industries operating for the reason that country. All these issues may impact industry and stable enlargement and industry attractiveness from stake holder's perspective.

The economic facet of research includes many factors. The first factor to consider is the current economic situation and fads in the united states where the industry is based. Companies should take note inflation and monetary decline so that when it involves spending, they can you shouldn't be financially affected. Failing to do this results within an economically blind system that could cause the industry's immediate collapse.

Another factor to consider in analysis is taxation rates. Whenever there are high taxation rates in a given country, price-based competition may affect a given industry in the international market. International financial movements are also very important, because they define forex rates, imports and exports.

Other factors to consider are consumer expenditure and throw-away income and, finally, legal issues, including all trade legislation in a given country and other legal legislation that inhibit or encourage development of business activities. Also to be considered are consumer coverage laws, employment laws, environmental protection laws and quality standardization legislation. Industrial regulations regulating competition, market policies and suggestions also play an important role in influencing industry's steadiness and future extension possibilities.

When considering the communal aspect, factors including demographic changes, shifts in worth and culture and lifestyle changes are important to notice so as to strategize on enlargement and expansion. Certain factors, such as media and communities, effect an industry's development and returns.

Brand name and corporate image are also very important in influencing development and returns given that they shape customer loyalty and shareholder investment. The media's views on certain industrial products should be integrated into the research, as should consumer attitudes and sensibility to "green" issues, that is, conditions that affect the surroundings, energy use and waste and its disposal.

A company's information systems and inner and external marketing communications also needs to be analyzed to ensure it keeps pace using its opponents. Other factors will be the insurance policies regulating education, health insurance and distribution of income, all of which, in the long run, influence consumer use of products.

The technological aspect of analysis has a variety of factors. Furthermore to developing technologies, all associated solutions, with their innovation potentials, acceleration of change and adoption of new technology, should be examined for a proper evaluation of the industry.

Other scientific factors are transport, misuse management and web business. The amount of expenses on R&D should also be considered to be able to secure the industry's competitive position to prevent loss and collapse.

1. 2. 3 Porter's Five Competitive Makes Analysis

Porter's model, as defined by Kay, can be an advancement of the Structure-Conduct-Performance paradigm conceived by Edward Mason at Harvard University in the 1930s and complete by Scherer in the 1980s. , The model seeks to determine the intensity of industry competition, major issues in identifying strategy and whether an industry is attractive or not.

Porter discovered five competitive makes that function on an industry and its environment: risk of entry, strength of rivalry among existing challengers, risk of substitutes, bargaining vitality of potential buyers and bargaining vitality of suppliers.

The first competitive power, threat of accessibility, refers to the risk of new entrants in an established industry or acquisition to gain market share. Reactions of individuals and obstacles to entry are the key factors used to determine whether the risk is high or low. Six major accessibility obstacles have been recognized

capital required to compete on the market (especially in high-risk industry, such as advertising or R&D)

switching costs

gain access to to distribution channels

economies of scale

cost disadvantages 3rd party of range, such as patents, usage of know-how, access to limited resources, favourable locations, administration subsidies or insurance policies and learning or experience curves

product differentiation

expected retaliation from existing companies contrary to the new entrants

Strong barriers to the admittance of new businesses enable a few companies to dominate the market and thereby impact prices.

The second make is strength of rivalry among existing competitors. Rivalry takes place when a number of firms inside an industry try to improve their position using tactics such as price competition, new product release or new services. Rivalry will depend on several factors: number and size of opponents, industry development, product characteristics (which determine whether the rivalry is dependant on price or differentiation), cost framework, exit barriers, diverse competitors, operative capacity and high tactical stakes.

If a business is inhibited, then businesses will experience issues when wanting to expand. The expansion of international competition and the corporate stakes also needs to be included in the analysis.

Threat of substitutes is the 3rd forces. Substitutes are those products made by other sectors but serving the same purposes as the initial product. These replacement products cause the demand to decline. The implications are reduced profits and reduced market command line by the initial capital investor. This is of particular importance when the customer has no switching costs and can simply compare products in conditions of price and efficiency.

Bargaining power of buyers is the fourth push. High bargaining electricity positions weak businesses inside the industry, forcing price down, boosting competition between industry players and resulting in bargaining for top quality or services. This vitality is specially high under certain conditions, such as few and specific clients, undifferentiated products, low turning costs, the possibility of backward integration and information about demand and the availability of selling price to the potential buyers.

Furthermore, bargaining ability is high if product quality is not a important factor of decision-making if what the customer is acquiring is a moderate small percentage of his total costs. Bargaining ability is even higher when the buyer is a dealer or a wholesaler in a position to effect the consumer's purchasing decision.

The fifth and previous push is the bargaining vitality of suppliers. This may act on the industry in several ways: increasing prices, decreasing quality or privileging some customers. Supplier vitality can be split into several elements.

One of these elements is supplier attention. Suppliers are in a more robust position whenever there are few suppliers, turning costs are high, the industry these are serving account for a small small fraction of the business or their products are an important part of the buyer's business. The bargaining electricity of suppliers is low or non-existent whenever there are substitute products. Finally, purchase quantity and the supplier's effect on cost are very important.

2. Pharmaceutical Industry Analysis

A general summary of the pharmaceutical industry is the primary objective of the section. First, this section will define the industry to be able to identify the main players in the pharmaceutical market. Second, using the equipment and models identified in the first section, it'll highlight the primary characteristics of the industry and the factors that influence it.

2. 1 Explanation of Pharmaceutical Industry

The pharmaceutical industry comprises companies developing, making and marketing products accredited for use as medications. Their goal is to prevent, diagnose or treat diseases. A medicinal product, also known as a pharmaceutical, in line with the EU, can be an exogenous chemical or a mixture of exogenous substances that may be organic and natural or inorganic, natural or artificial, and able, once inside the human being or dog body, to change physiological functions or to make a medical examination through physical, chemical or physicochemical action.

This industry is subdivided into two sub-industries seen as a different business models and players: prescription and OTC pharmaceuticals. Prescription pharmaceuticals, also referred to as "Rx, " are medicines that exist to the consumers for purchase in a pharmacy or medication store only with a prescription from a physician or administered only in private hospitals.

These medicines aim for specific diseases and, therefore, are recommended for and used by one individual only. OTC pharmaceuticals are instead employed by more than one person which present the same symptoms in the same or in several time. These drugs are available to the buyer at each and every time and the buyer don't need any prescription from a physician for sale.

Furthermore, inside this industry there are two types of businesses: Big Pharma and Biotech. These two types, despite being in the same business, change in a number of ways: IP, medication methodology, expenditure and production of R&D. The primary medicine R&D techniques employed by Big Pharma companies are chemoinformatics and in silico screenings. Biotech companies are companies that use biotechnology in R&D.

Biotechnology, according to the Organization for Economic Assistance and Development, is "the use of science and technology to living organisms, as well as parts, products and models thereof, to improve living or nonliving materials for the production of knowledge, goods and services. "

Generally, Biotech companies tend to have a strong educational culture, are more risk treatment and spend less than half what Big Pharma spends on R&D; in 2004, Biotech companies spent $20 billion, versus $50 billion spent by Big Pharma. Generally, a Biotech product has multiple IP covering make, formulation and stableness, as opposed to Big Pharma IP, which protects only the product, allowing generics to be produced quickly.

While they could appear to have the same phenotype, their genotypes are particular, so much so that they can be looked at two industries, as explained by Arthur D. Levinson, Chairman and CEO of Genentech. Nevertheless, this distinction is not always clear, as much Biotech and Big Pharma firms are hybrids to varying degrees.

The focus of the thesis are Big Pharma mixed up in development of prescription pharmaceuticals to take care of and prevent human diseases in the European union market.

2. 2 Analysis of the Pharmaceutical Industry

The purpose of this section is to give a brief overview of the pharmaceutical industry lifecycle and research the major power acting inside it.

2. 2. 1 Industry Lifecycle Analysis

People over time have always tried out to find diseases causes and also to find remedies against it. The most complete medical test, the Ebers Papyrus, is dated 1550 BC and it was written by Egyptians. However, the industrial development of drugs dates back to the year 1827 when Heinrich E Merck in Germany founded the first company for the creation of cocaine and morphine. This event started out the introduction phase of the pharmaceutical industry in European countries.

In European countries, this industry was born in different way, reflecting the various strategic groups within it. Within the German-speaking countries, pharmaceutical companies were born as a branch of the chemical industry, with businesses like Bayer and Hoechst in 1863, BASF in 1865 and Schering in 1871 in Germany, and CIBA in 1884 and Sandoz in 1886.

Only Hoffman-La Roche in 1894 in Switzerland was originally a drug organization. On the other hand, in Italy, France and the UK companies were blessed from small shop pharmacies, such as Glaxo which traces its origins to a pharmacy in Plough Court in 1715. During the 1800s many compounds were already being isolated, but nothing had been synthetically produced.

The first fabricated medication was Phenacetin, produced by Bayer and commercialized in 1888. A decade later Bayer commercialized Aspirin, which marked a milestone in the pharmaceutical industry. Many firms rose to prominence in the 1920s-30s with these kinds of pharmaceuticals, but also with a fresh school of pharmaceuticals: vaccines and serums.

During the Second World Warfare II the demand for drugs increased and mass production started, mainly with drugs such as antibiotics (penicillin, streptomycin and neomycin) and sulphonamide. The availability of these drugs dramatically changed the product quality and the common life-span of individuals. In this era the German pharmaceutical industry, a head combined with the Swiss in pre-war times, was bought out by American companies who emerged to Europe to taking good thing about the condition of the continent following the war.

The period 1950-60 was the beginning of the industry's progress phase, which saw a proliferation of new drugs and high return to drug breakthrough. New drugs included tranquilizers such as MAO inhibitors in 1952, anti-tuberculosis drugs such as Isoniazid in 1952 and oral contraceptives in 1956. Other discoveries included Librium in 1960 and Valium in 1960. The last mentioned was sold from 1963 and later became one of the very most prescribed medicines in history before controversy emerged over its connect to habituation and dependency.

In the 1950s, legislation was put in place to control the industry, mainly touching on labelling and authorization by health government bodies as well as pulling distinctions between non-prescription and prescription medications. In this seemingly unstoppable process of pharmaceutical progression and optimism the industry was stalled with a drama concerning one drug sold in Europe and Japan, Thalidomide.

This medicine, synthesized in Germany in 1954, was launched to the marketplace to take care of the symptoms of day sickness and nausea in pregnant women. Between 1954 and 1960, it caused around 5, 000 and 10, 000 severe deformities in babies. Actually, the drug was not sufficiently tested on animals to determine its safety, and after this revelation, in an attempt to better regulate the industry, medicine oversight authorities were founded to exercise control over the industry.

The World Medical Relationship attained in Finland and granted the Declaration of Helsinki, establishing the specifications for clinical research. Among other things, the declaration mentioned that pharmaceutical companies must show the efficiency of a fresh drug in specialized medical trials before liberating it to the marketplace, and subjects must consent to experiments done to check the efficiency of drugs in specialized medical studies.

The industry continued to be small up to the past due 1970s. Two events characterized the 1970s. First, chemical substance production for raw materials and early intermediates shifted out of European countries to low cost places such as India and China which later began producing lively pharmaceutical ingredients and lastly non-patented pharmaceuticals. Second, there is the birth of biotechnology.

This new research had its root base a long time before with the breakthrough of the double helix in 1953 by Watson and Crick, which followed the improvements in molecular genetics, recombinant DNA technology, and molecular biology. Until then, drugs in business were produced by extraction from natural substances or chemical synthesis.

These new techniques of molecular biology marked the delivery of a fresh industry which became a rival to and an alternative of the pharmaceutical industry. This new industry was pioneered by firms like Genentech and Amgen which created cutting edge drugs such as Epogen and recombinant individuals insulin.

In the 1980s, legislation was approved in most Europe necessitating adherence to strong patents for both the pharmaceutical products and their development processes. There were also new polices like the introduction of the Good Clinical Practices, which were recommendations regulating ethics and the dependability of specialized medical studies.

In Europe, several says also initiated health maintenance organizations and been able care in order to limit growing medical costs, and a choice for precautionary rather that curative medication took root.

As the industry inserted the 1990s, new discoveries and projects, such as the Human Genome Task 1990, changed the business enterprise environment. Also, there is a huge influx of M&A to make on synergies. This included Ciba-Geigy and Sandoz building Novartis, Hoechst and Roussel-Rhone Poulenc-Rorer developing Aventis and Glaxo Wellcome and SmithKline building GlaxoSmithKline.

In this way, the processing of pharmaceuticals had become concentrated in Western Europe and THE UNITED STATES, with dominant businesses and some small companies that produced drugs in each country. The major Western companies are still the dominating players not only in Europe but also in the global market. They include Novartis of Switzerland, Bayer of Germany, GlaxoSmithKline of the UK, Hoffman-la Roche of Switzerland and AstraZeneca of UK/Sweden.

As the European pharmaceutical industry entered the 21st hundred years, indications of the development phase have become even more noticeable. It has been seen as a powerful marketing to doctors and internet commerce. This, partly, has been facilitated by the liberalization of marketing rules requiring presentation of dangers as well as the advertising meaning. Internet has allowed the immediate purchase of recycleables by the manufacturers.

The development of drugs has changed from the hit-and-miss approach to research and up to date discovery. Alternative medicines and lifestyle medications have shown new issues and opportunities and have raised the level of competition on the market.

The ageing people in western European economies has increased opportunities for elevating revenues. Actually, as a result of ageing human population in the developed economies, drug consumption will increase because the aged have a higher rate of recurrence of contracting diseases than more youthful people. New epidemics, including the recent H1N1 flu outbreak, continue to batter the earth human population, and increased globalization makes them distributed more quickly than ever before.

As the industry advancements through the growth period, companies are executing research and development initiatives both to build up new drugs and improve creation procedures. Further, the increased role of state-supported medical strategies across Europe, and also other state-managed health programs about the world will greatly improve the reach of healthcare, increasing it to more of the middle class and the indegent who constitute the larger part of the population generally in most countries.

As the medical programs continue to gain efficiency, the sales of pharmaceutical businesses are expected to grow. Furthermore, the growing economies like Brazil, Russia, India, China, Turkey, Mexico, and South Korea will increase potential consumer figures on the market for Western manufacturers.

Together, these countries constitute a huge percentuage of the world's society, and therefore their entry in to the high income category will without doubt present an enormous potential market for pharmaceutical products.

In simple fact, the growth in these markets is likely to reach 14-17% by 2014, weighed against only 3-6% growth in the developed marketplaces. Thanks to contracts authorized by the Asia-Pacific and European countries governments related to liberalization of the Asia-Pacific pharmaceuticals and ventures market, many companies have already started to create relationships with appearing markets.

An example is GlaxoSmithKline, who partnered in 2009 2009 with India's Dr. Reddy Laboratories. GlaxoSmithKline will send out the drugs made and supplied by Dr. Reddy in Africa, the Middle East, Asia-Pacific, and Latin America.

Even with these previous considerations, the European pharmaceutical industry has only a limited chance of getting into the maturity stage of the pattern. The obstacles to access are so excellent that they choke any new entrant in nearly every facet of procedure: in research and development, in product circulation, and in compliance with rules and regulations.

In simple fact, this industry has intricate manufacturing capabilities that happen to be hard to replicate, and are guarded through patent, as well as huge consumer attachment to preferred brands from specific companies, often prepared by experience. Furthermore Europe generic penetration is suprisingly low (less than 10% in total). Thus the industry might stay in the growth phase for a significant time.

Also We Can Offer!

Other services that we offer

If you don’t see the necessary subject, paper type, or topic in our list of available services and examples, don’t worry! We have a number of other academic disciplines to suit the needs of anyone who visits this website looking for help.

How to ...

We made your life easier with putting together a big number of articles and guidelines on how to plan and write different types of assignments (Essay, Research Paper, Dissertation etc)